card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

A Pan-Cancer View of the Immune Landscape in the Tumor Microenvironment via RNA and their Potential for Biomarkers in Clinical Trials

Immune-based biomarkers for measurement of tumor microenviornment (TME)
Home / Insights / A Pan-Cancer View of the Immune Landscape in the Tumor Microenvironment via RNA and their Potential for Biomarkers in Clinical Trials

Author: Wendell Jones

Immune-based biomarkers are now commonly available when measuring the tumor microenvironment (TME), although many are based on immuno-histochemistry methods which sometimes have drawbacks: specificity, quantitation, variety. In addition, next-gen RNA sequencing and focused RNA assays are now much more accessible (for example, processing formalin-fixated material has a much higher degree of success) and are commonly employed in clinical trials to measure tumor activity and immune cell content in the TME. Download our poster from SITC 2018 to learn about our gene signatures for immune activity.

Complete the form below to access this scientific poster